| Chen, Feng |
| Active, not recruiting | 1/2 | 196 | RoW | CAR T-cell therapy | The First Affiliated Hospital of Soochow University, Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd, The Second People's Hospital of Huai'an, Third Military Medical University | Acute Lymphoblastic Leukemia with Failed Remission | 08/24 | 12/25 | | |
| Liu, Ying Su |
NCT04468529: Evaluate the Effect of Injectable Neucardin on the Cardiac Function of Subjects With Chronic Systolic Heart Failure |
|
|
| Completed | 3 | 154 | RoW | Recombinant human Neuregulin for injection, Neucardin, Placebo | Zensun Sci. & Tech. Co., Ltd. | Chronic Systolic Heart Failure | 04/22 | 04/24 | | |
| Recruiting | 3 | 918 | Europe, Canada, Japan, RoW | Zanidatamab, ZW25, JZP598, Tislelizumab, Trastuzumab, Herceptin®, Capecitabine, Oxaliplatin, Cisplatin, 5-Fluorouracil | Jazz Pharmaceuticals, BeiGene, Ltd. | Gastric Neoplasms, Gastroesophageal Adenocarcinoma, Esophageal Adenocarcinoma | 05/25 | 05/26 | | |
PANOVA-3, NCT03377491: Effect of Tumor Treating Fields (TTFields, 150 kHz) as Front-Line Treatment of Locally-advanced Pancreatic Adenocarcinoma Concomitant With Gemcitabine and Nab-paclitaxel |
|
|
| Completed | 3 | 571 | Europe, Canada, US, RoW | NovoTTF-200T, TTFields, Gemcitabine, nab paclitaxel | NovoCure Ltd. | Pancreas Adenocarcinoma | 10/24 | 10/24 | | |
JSKN003-302, NCT06079983: JSKN003 Versus Treatment Of Physician'S Choice For HER2-low, Unresectable and/or Metastatic Breast Cancer Subjects |
|
|
| Not yet recruiting | 3 | 400 | RoW | JSKN003, Capecitabine tablets, Gemcitabine hydrochloride for injection, Vinorelbine tartrate injection, Paclitaxel for injection (albumin-bound type), Docetaxel injection, Eribulin mesylate injection | Jiangsu Alphamab Biopharmaceuticals Co., Ltd | Breast Cancer | 04/25 | 03/29 | | |
STRIDES, NCT05490563: - a Clinical Research Study of an Investigational New Drug to Treat Spinocerebellar Ataxia |
|
|
| Terminated | 2/3 | 23 | Europe, US, RoW | SLS-005, Placebo | Seelos Therapeutics, Inc. | Spinocerebellar Ataxia Type 3 | 11/23 | 11/23 | | |
MRG002-002, NCT04837508: A Study of MRG002 in the Treatment of HER2-positive Unresectable, Locally Advanced or Metastatic Biliary Tract Cancer |
|
|
| Recruiting | 2 | 86 | RoW | MRG002 | Shanghai Miracogen Inc. | Advanced or Metastatic Biliary Tract Cancer | 12/22 | 08/23 | | |
NCT05188209: A Study to Evaluate the Efficacy and Safety of MRG003 in Patients With Advanced Gastric Cancer. |
|
|
| Recruiting | 2 | 60 | RoW | MRG003 | Shanghai Miracogen Inc. | Advanced or Metastatic Gastric Cancer, Advanced or Metastatic Gastroesophageal Junction Carcinoma | 03/23 | 08/23 | | |
NCT05247216: A Phase 2 Study of Hemay007 in Patients With Rheumatoid Arthritis |
|
|
| Completed | 2 | 140 | RoW | Hemay007 800 mg QD group, Hemay007 1200 mg QD group, Hemay007 600 mg QD group, Hemay007 placebo group | Tianjin Hemay Pharmaceutical Co., Ltd | Rheumatoid Arthritis | 06/23 | 06/23 | | |
NCT06173037: RC88 in Platinum-Resistant Recurrent Epithelial Ovarian Cancer, Fallopian Tube Cancer, and Primary Peritoneal Cancer |
|
|
| Recruiting | 2 | 88 | RoW | RC88, RC88 for Injection | RemeGen Co., Ltd. | Primary Peritoneal Cancer, Fallopian Tube Cancer, Epithelial Ovarian Cancer | 06/26 | 12/26 | | |
NCT04774419: Radiation and TSR-042 (Dostarlimab) in People With Endometrial Cancer After They Receive Surgery |
|
|
| Recruiting | 2 | 62 | US | Intensity modulated radiation therapy (IMRT), Dostarlimab, TSR-042, Hypofractionated IMRT | Memorial Sloan Kettering Cancer Center, Tesaro, Inc. | Endometrial Cancer | 02/26 | 02/26 | | |
ACTIVATE, NCT05819359: Efficacy, Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of BIA 28-6156 in GBA-PD |
|
|
| Active, not recruiting | 2 | 237 | Europe, Canada, US | BIA 28-6156 10 mg, BIA 28-6156 60 mg, Placebo | Bial R&D Investments, S.A. | Parkinson's Disease | 03/26 | 07/26 | | |
NCT06166836: a Study to Evaluate the Safety and Efficacy of D-1553 Combined With IN10018 in KRAS G12C Mutant Solid Tumors |
|
|
| Recruiting | 1/2 | 140 | RoW | D1553, IN10018（Ifebemtinib）, BI 853520 | InxMed (Shanghai) Co., Ltd., InventisBio Co., Ltd | Solid Tumor | 12/25 | 12/26 | | |
NCT04755543: A Study of LP002 for the Treatment of Patients With Malignant Digestive System Neoplasms |
|
|
| Recruiting | 1 | 94 | RoW | LP002, Cisplatin, Fluorouracil, OH2 oncolytic virus | Taizhou HoudeAoke Biomedical Co., Ltd. | Digestive System Neoplasms | 06/21 | 06/22 | | |
| Recruiting | N/A | 70 | US | | Koneksa Health, Merck Sharp & Dohme LLC, Regeneron Pharmaceuticals | Parkinson Disease | 08/25 | 09/25 | | |
| Tian, Jing |
NCT05688696: Evaluate the Efficacy and Safety of Orelabrutinib in Adult Patients With Systemic Lupus Erythematosus |
|
|
| Recruiting | 2 | 186 | RoW | Orelabrutinib (Low Dose), Orelabrutinib (High Dose), Orelabrutinib Placebo | Beijing InnoCare Pharma Tech Co., Ltd. | Systemic Lupus Erythematosus, SLE | 08/25 | 05/26 | | |
NCT06010901: A Clinical Study of TQB2618 Injection Monotherapy and Combination Regimen (With Penpulimab Injection ±Anlotinib Hydrochloride Capsules) in the Four or Later Lines of Treatment of Advanced Colorectal Cancer. |
|
|
| Recruiting | 1 | 75 | RoW | TQB2618 injection, Penpulimab injection, Anlotinib hydrochloride capsules | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Colorectal Cancer | 03/25 | 07/25 | | |
| Xiang, Yin |
| No trials found |
| Huang, Huiying |
| No trials found |
